First Use of Maribavir in Poland to Treat Refractory CMV Disease in a Patient After Kidney Transplantation

IF 0.8 4区医学 Q4 IMMUNOLOGY

Transplantation proceedings Pub Date : 2025-02-24 DOI:10.1016/j.transproceed.2025.02.008

Anna Pawłowska, Norbert Kwella, Justyna Zbrzeźniak-Suszczewicz, Monika Knysak, Tomasz Stompór

引用次数: 0

Abstract

Cytomegalovirus (CMV) is one of the most common opportunistic infections affecting solid organ transplant recipients (SOTRs). In this article, we presented the case of a 39-year-old patient with end-stage renal disease after kidney transplantation with refractory CMV infection, who was successfully treated with maribavir for the first time in Poland. The use of maribavir resulted in a significant reduction of CMV viremia in ganciclovir/valganciclovir-resistant CMV infection and resolution of CMV disease symptoms in the absence of drug-related adverse events.

查看原文本刊更多论文

波兰首次使用马里巴韦治疗肾移植后难治性巨细胞病毒病。

巨细胞病毒（CMV）是影响实体器官移植受者（SOTRs）最常见的机会性感染之一。在这篇文章中，我们报道了一例39岁的肾移植后终末期肾脏疾病患者合并难治性巨细胞病毒感染的病例，他在波兰首次成功地接受了马里巴韦治疗。使用马里巴韦可显著减少更昔洛韦/缬更昔洛韦耐药巨细胞病毒感染的巨细胞病毒血症，并在没有药物相关不良事件的情况下缓解巨细胞病毒疾病症状。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transplantation proceedings 医学-免疫学

CiteScore

1.70

自引率

0.00%

发文量

502

审稿时长

60 days

期刊介绍： Transplantation Proceedings publishes several different categories of manuscripts, all of which undergo extensive peer review by recognized authorities in the field prior to their acceptance for publication. The first type of manuscripts consists of sets of papers providing an in-depth expression of the current state of the art in various rapidly developing components of world transplantation biology and medicine. These manuscripts emanate from congresses of the affiliated transplantation societies, from Symposia sponsored by the Societies, as well as special Conferences and Workshops covering related topics. Transplantation Proceedings also publishes several special sections including publication of Clinical Transplantation Proceedings, being rapid original contributions of preclinical and clinical experiences. These manuscripts undergo review by members of the Editorial Board. Original basic or clinical science articles, clinical trials and case studies can be submitted to the journal?s open access companion title Transplantation Reports.